Abstract: BACKGROUND: Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed worldwide since 2008 for the primary and secondary prevention and treatment of thromboembolic disorders. Although liver injury was observed in premarketing trials of rivaroxaban, there are no published postmarketing cases of liver injury associated with rivaroxaban. METHODS: Report of 14 cases of liver injury associated with rivaroxaban, including two with liver biopsy, and search queries in three large international pharmacovigilance databases for comparable cases. RESULTS: Formal causality assessment classified rivaroxaban as the "highly probable", "probable" and "possible" cause in 4, 7 and 3 patients, respectively. Search results from three large international pharmacovigilance databases revealed a considerable number of additional hepatic adverse events where rivaroxaban was reported as a suspected cause. CONCLUSIONS: We interpret the presented information as a relevant safety signal that should be followed by pharmacoepidemiological studies in order to reliably estimate absolute and relative risks of liver injury associated with rivaroxaban in support of rational risk-benefit assessment. Meanwhile, incident symptoms and signs of liver disease in patients treated with rivaroxaban should be considered as a potential adverse drug reaction, and if no other likely cause can be identified rivaroxaban should be stopped as soon as possible. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 
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INTRODUCTION
Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed worldwide since 2008 for the primary and secondary prevention and treatment of thromboembolic disorders [1, 2] . Although liver injury was observed in premarketing trials of rivaroxaban [3] , postmarketing cases of liver injury associated with rivaroxaban have not been published so far. Safety issues of newly marketed drugs including drug-induced liver injury (DILI) are typically identified during the first five years after marketing, and spontaneous reporting systems play an important role as a sensitive source of information for the detection of new postmarketing safety signals. We therefore evaluated postmarketing cases of liver injury associated with rivaroxaban reported to our regional pharmacovigilance center and performed search queries in three large international pharmacovigilance databases for comparable cases.
CASE PRESENTATIONS

Case #1
A 78-year-old male patient had total knee replacement for which he received thromboprophylaxis with dalteparin for 10 days and thereafter rivaroxaban (Xarelto Rivaroxaban was stopped 19 days after start, but it was not until another 10 days later that the patient was rehospitalized with determination of laboratory values. Upon admission alanine aminotransferase (ALT), alkaline phosphatase (AP) and total bilirubin (TB) were increased 2.5, 2.9 and 15.5 times the upper limit of normal (ULN), respectively. Viral serology and autoantibodies were negative. Abdominal ultrasound and computer tomography (CT) showed cholecystolithiasis but no signs of biliary obstruction. A liver biopsy was performed 20 days after discontinuation of rivaroxaban. Histology showed cholestasis and portal inflammation with eosinophilic infiltrates, compatible with drug-induced liver injury (Figure) .
Other recently administered drugs were a single i.v. dose of 2g cefazolin before knee replacement and postoperative analgesic treatment with acetaminophen and metamizole (=dipyrone) up to 4 g/day each for 10 days. During the further course the patient eventually developed a paralytic ileus and died 6 weeks after rehospitalization. The findings are also summarized in Table 1 .
According to standardized RUCAM criteria for the assessment of drug-induced liver injuries [4] [5] [6] we assigned a causality of "highly probable" (total score: 9) to rivaroxaban. Key criteria for this assessment were a close and plausible temporal relationship, a known and labeled adverse drug reaction, compatible histological findings, and negative differential diagnosis for alternative causes. Specifically, temporal relationship, only mild ALT increase and histology were not compatible with acetaminophen hepatotoxicity; dalteparin and metamizole had been stopped approximately 14 days, and cefazolin single dose was given 24 days before onset of symptoms. Other drugs were therefore classified as unlikely alternative causes.
Case #2
An 83-year-old female patient had total knee replacement for which she received thromboprophylaxis with dalteparin for 9 days and thereafter rivaroxaban 10 mg/d. Approximately 13 days after start of rivaroxaban the patient developed painless jaundice, pruritus, fatigue, nausea and unintentional weight loss of 5 kg. Twenty days after start of rivaroxaban the patient was rehospitalized, and another day later rivaroxaban was replaced by dalteparin. Upon admission ALT, AP and TB were increased 7.8, 6.8 and 13.9 times the ULN, respectively (Table 1 ). Viral serology and autoantibodies were negative. Abdominal Formal RUCAM assessment classified rivaroxaban's causality as "possible" (total score: 5), based on the key criteria of a close and plausible temporal relationship, a known and labeled adverse drug reaction, compatible histological findings and negative differential diagnosis for alternative causes except for diclofenac use. Nevertheless, in contrast to rivaroxaban, fixeddose diclofenac was stopped 16 days before onset of symptoms, and rivaroxaban therefore remains the most likely cause of liver injury.
Cases #3-14
Over the past 4 years and in our function as a regional pharmacovigilance center we received another 12 reports of liver injury associated with rivaroxaban and an at least possible causal relationship based on RUCAM criteria. In addition to our primary documentation we now performed an extensive reevaluation including formal causality assessment. For that purpose we contacted primary reporters and other treating physicians and hospitals and obtained all available relevant follow-up information. These cases are summarized in Table 1 , and their detailed RUCAM classifications are presented in Table 2 .
REPORTS IN INTERNATIONAL PHARMACOVIGILANCE DATABASES
Cases of liver injury associated with rivaroxaban should be reported to pharmacovigilance systems worldwide, and we therefore also performed searches in databases of international These reports have limitations and must therefore be interpreted with caution: in the absence of detailed information the causal role of rivaroxaban regarding the reported hepatic outcomes remains uncertain; due to unknown reporting rates and population exposure spontaneous reporting systems cannot provide reliable quantitative risk estimates; pharmacovigilance systems may contain duplicate reports, and in our EudraVigilance search several adverse events may refer to only one individual case. Nevertheless, these reports can be interpreted as a signal in support of the hypothesis that our cases may represent just the "tip of the iceberg" of a considerably larger number of serious liver injuries worldwide caused by rivaroxaban.
DISCUSSION
Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed worldwide since 2008 for the primary and secondary prevention and treatment of thromboembolic disorders.
Five years after market launch we are not aware of any published detailed postmarketing case reports of liver injury associated with rivaroxaban. However, liver injury is known under rivaroxaban, labeled adverse reactions include icterus and increased transaminases, alkaline phosphatase, and total and conjugated bilirubin [7] . Of note, the direct thrombin inhibitor ximelagatran was associated with hepatotoxicity during clinical development, which contributed to non-approval by the US FDA, and in other countries marketing was discontinued after serious cases of liver injury associated with ximelagatran appeared in the postmarketing phase [8] . Looking at premarketing data of rivaroxaban, a published evaluation of rivaroxaban's hepatic events in clinical trials was based on its phase III RECORD studies and included 6131 patients exposed to rivaroxaban. The featured analysis used state of the art eDISH plots [3] and identified ALT increases ≥3x ULN in 2.3% of patients including 9 apparent "Hy's cases" with a simultaneous ≥2x increase in total bilirubin.
Further validations concluded that there was only one "true" Hy's case either caused by rivaroxaban or possibly by other incompletely excluded alternate etiologies [3] . A recent systematic review and meta-analysis of premarketing data on liver injury associated with new oral anticoagulants reported ambiguous results. There were a large number of cases with ALT elevations >3x ULN including many with concomitant total bilirubin >2x ULN subsequent to the use of those drugs. At the same time there were no evident risk differences between the individual studied new oral anticoagulants, and a lower risk of such events when compared to low molecular weight heparins [9] . However, safety analyses of clinical trials' data have intrinsic limitations. According to the "Rule of 3" [10, 11] the 6131 exposed patients in the RECORD studies are insufficient to reliably detect risks of less than approximately 1:2000, which is typical for idiosyncratic drug-induced liver disease (DILI) but can still be relevant for a drug's overall risk-benefit evaluation [12] . Another limitation is that the duration of treatment in these trials was only 35±2 or 12±2 days, respectively [3] . This is shorter than the currently labeled treatment time for some indications, and 12±2 days are also less than the median latency time of 15.5 days in our case series. Risk factors are another issue of particular interest, as they are often underrepresented in clinical trial populations.
Rivaroxaban is often started after orthopedic surgery and many patients concomitantly receive potentially hepatotoxic analgesic drugs. Our series included three patients meeting biochemical criteria of Hy's cases but concomitant use of acetaminophen in therapeutic doses. Dose, long latency time and histology were not compatible with acetaminopheninduced hepatotoxicity in these cases. However, according to current mechanistic concepts acetaminophen in doses below the hepatotoxic threshold may attenuate hepatotoxic "downstream" pathways via glutathione depletion and cytokine-mediated signal transduction.
Acetaminophen could therefore have acted as a risk factor for rivaroxaban-induced liver injury [13, 14] . Some patients also received metamizole, but hepatotoxicity is not amongst its labeled adverse reactions. Indeed, we found only one case of metamizole-associated liver injury in the literature [15] , but it presented with an allergic skin reaction after short latency, which is different from the pattern observed in our cases. In order to further clarify the causality in our case series, we planned the conduct of lymphocyte transformation tests (LTT) with in-vitro exposure of lymphocytes from our patients to rivaroxaban. This method has been successfully used for the evaluation of DILI in the past [16] . These planned studies have been delayed because we were unable to obtain rivaroxaban pure substance from the manufacturer of Xarelto ® , but we now aim to perform these tests with commercially available rivaroxaban.
Possible mechanisms of rivaroxaban-induced hepatotoxicity are unknown and probably involve complex interactions of several rare factors, possibly also immune-mediated reactions. Of further note, previous studies indicated that rivaroxaban is a shared substrate of the drug transport proteins MDR1 and BCRP, whereas anticoagulant vitamin K antagonists are no strong substrates of MDR1 [17] [18] [19] . MDR1 inhibitors and loss-of-function BCRP polymorphisms may therefore alter rivaroxaban pharmacokinetics, and further studies may explore the potential role of these factors for rivaroxaban-induced DILI.
The diagnosis of drug-induced liver injury mainly depends on temporal relationship and the exclusion of other causes, which can never be done with absolute certainty. Furthermore, even the widely accepted RUCAM causality scale for DILI has limitations, and discrepancies between expert evaluations vs. standardized scales have been widely discussed and studied [6, 20, 21] . At least all cases reported to our center were evaluated using senior expertise and the most recognized standardized DILI-specific criteria. In contrast, the routine evaluation of cases that are reported to large pharmacovigilance databases usually lacks detailed case information and sufficient resources for standardized DILI-specific causality assessments. In order to avoid over-interpretation it is therefore reasonable that publicly available search results from those databases only contain the information whether a specific drug is considered as an at least possible cause. Furthermore, we also recognize that some individual cases may have been reported to more than one of the searched databases.
Spontaneous reports are neither meant to provide definite proof for the causative role of rivaroxaban in the presented cases, nor can they be used for reliable calculations of quantitative risk estimates. However, we applied the best possible combination of standardized causality assessment plus expert evaluation, and in our long-term experience as a pharmacovigilance center the presented case series of liver injury in association with a newly marketed drug is unusual and reason to raise concern. Premarketing experience and information from international pharmacovigilance databases are also compatible with the possibility that rivaroxaban continues to cause a considerable absolute number of liver injuries worldwide. In conclusion, we therefore interpret the presented case series as a potentially serious signal that requires follow-up by pharmacoepidemiological cohort studies in suitable databases in order to estimate the absolute and relative risks of serious liver injury associated with rivaroxaban versus alternative anticoagulants [12] . Meanwhile, the apparently rare but potentially serious risk of rivaroxaban-induced liver injury should be considered in the risk-benefit evaluation versus alternative antithrombotic drugs with established safety profiles. In patients treated with rivaroxaban incident symptoms and signs of liver disease should be considered as a potential adverse drug reaction, and if no other likely cause can be identified rivaroxaban should be stopped as soon as possible.
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